Harbin Pharmaceutical Group Co., Ltd. (600664) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Harbin Pharmaceutical Group Co., Ltd.

Why is Harbin Pharmaceutical Group Co., Ltd. ?

With a fall in EPS of -49.4%, the company declared Very Negative results in Sep 25

OPERATING CASH FLOW(Y) Lowest at CNY 281.12 MM
ROCE(HY) Lowest at 8.26%
INTEREST COVERAGE RATIO(Q) Lowest at 881.47

Below par performance in long term as well as near term

Along with generating -2.79% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Harbin Pharmaceutical Group Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Harbin Pharmaceutical Group Co., Ltd. for you?

Low Risk, Medium Return

Absolute

Risk Adjusted

Volatility

Harbin Pharmaceutical Group Co., Ltd.

-15.22%

1.08

23.75%

China Shanghai Composite

20.18%

1.58

14.20%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

7.28%

EBIT Growth (5y)

21.67%

EBIT to Interest (avg)

5.31

Debt to EBITDA (avg)

1.06

Net Debt to Equity (avg)

0.05

Sales to Capital Employed (avg)

1.86

Tax Ratio

20.25%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

8.92%

ROE (avg)

9.35%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.34

EV to EBIT

14.96

EV to EBITDA

10.50

EV to Capital Employed

1.36

EV to Sales

0.46

PEG Ratio

Dividend Yield

ROCE (Latest)

9.10%

ROE (Latest)

5.82%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

7What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CNY 718.45 MM

CASH AND EQV(HY)

Highest at CNY 6,618.7 MM

DEBT-EQUITY RATIO (HY)

Lowest at -6.78 %

NET SALES(Q)

Highest at CNY 4,175.17 MM

NET PROFIT(Q)

At CNY 161.13 MM has Grown at 78.25%

-11What is not working for the Company

NET PROFIT(HY)

At CNY 194.14 MM has Grown at -41.79%

ROCE(HY)

Lowest at 5.42%

RAW MATERIAL COST(Y)

Grown by 6.66% (YoY

DEBTORS TURNOVER RATIO(HY)

Lowest at 2.92 times

Here's what is working for Harbin Pharmaceutical Group Co., Ltd.

Operating Cash Flow

Highest at CNY 718.45 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Net Sales

Highest at CNY 4,175.17 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (CNY MM)

Net Profit

At CNY 161.13 MM has Grown at 78.25%

over average net sales of the previous four periods of CNY 90.4 MM

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

Cash and Eqv

Highest at CNY 6,618.7 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio

Lowest at -6.78 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Here's what is not working for Harbin Pharmaceutical Group Co., Ltd.

Debtors Turnover Ratio

Lowest at 2.92 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Raw Material Cost

Grown by 6.66% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales